This invention is of particular use to patients with Diabetes Mellitus. It uses alkyl analogs of the methyl pyruvate (MP) family to provide energy and improve insulin and glucose homeostasis via accelerated intracellular delivery of protons and ATP from each MP. The energy upregulates cellular cross
This invention is of particular use to patients with Diabetes Mellitus. It uses alkyl analogs of the methyl pyruvate (MP) family to provide energy and improve insulin and glucose homeostasis via accelerated intracellular delivery of protons and ATP from each MP. The energy upregulates cellular cross talk and networking resulting in a surge of ATP enabling NADH (via glycolysis) that enables pancreatic islet cells to obtain increased ATP allowing excess insulin manufacture. This process improves cellular respiration and expedites protein, lipid and hormone manufacture. The increased energy also enables telomeres and delays Hayflick limit. Instead of cellular repair, silence, or apoptosis, energy is allocated for cell/organ function. This invention curbs inflammation and ROS by idealizing cellular respiration and diminishing hyperglycemia. In turn a reduction of advanced glycation end products (AGEs), lessened target RNA and nucleic acid toxins, i.e., diminished HbA1c occurs. By decreased drain of cellular energy, genomic function improves.
대표청구항▼
1. A method of treating a patient afflicted with Diabetes Mellitus to reduce HbA1c of said patient in which energy is provided to energy deprived cells of said patient, said method consisting of administering, to said patient afflicted with said Diabetes Mellitus, a therapeutically effective amount
1. A method of treating a patient afflicted with Diabetes Mellitus to reduce HbA1c of said patient in which energy is provided to energy deprived cells of said patient, said method consisting of administering, to said patient afflicted with said Diabetes Mellitus, a therapeutically effective amount of methyl pyruvate and ethyl pyruvate together with at least one additional agent, so as to provide said energy to said energy deprived cells via a citric acid cycle and so as to reduce said HbA1c of said patient; wherein said at least one additional agent is selected from the group consisting of acetyl L-carnitine, taurine, inosine, magnesium chloride, magnesium L-threonate, alpha lipoic acid, vitamin E in the form of alpha and gamma tocopherol, vitamin D3 and niacin. 2. The method according to claim 1, wherein said therapeutically effective amount of said methyl pyruvate and said ethyl pyruvate ranges is from about 1 microgram to about 100 grams at least once a day. 3. The method according to claim 1, wherein said therapeutically effective amount of said methyl pyruvate and said ethyl pyruvate ranges from about 1 microgram to about 50 grams per day and is administered in divided doses more than once a day. 4. The method according to claim 1, wherein said therapeutically effective amount is from about 1 to about 4 grams per day in eight ounces of water per gram of said methyl pyruvate. 5. The method according to claim 1, wherein said therapeutically effective amount comprises 2 grams of said methyl pyruvate at least once a day, said methyl pyruvate being diluted in water at a concentration of one gram of said methyl pyruvate per liter of water. 6. The method according to claim 1, wherein said administration provides said energy for the citric acid cycle that bypasses any prior cellular/mitochondria preparation. 7. The method according to claim 6, wherein said provided energy upregulates cellular crosstalk and networking. 8. The method according to claim 6, wherein said provided energy allows said energy depleted cells to proceed to a homeostatic state. 9. The method according to claim 1, wherein said provided energy increases the manufacture of proteins, lipids, and hormones via the mRNA at the ribosomes of the endoplasmic reticulum. 10. The method according to claim 1, wherein said provided energy increases ATP in said energy deprived cells, and wherein said increased ATP upregulates and restores specific cellular function of said energy deprived cells. 11. The method according to claim 1, wherein said provided energy diminishes inflammation in said cells. 12. The method according to claim 1, wherein said provided energy allows said energy deprived cells to manufacture insulin, said manufactured insulin reducing elevated blood glucose levels, and said reduction of said elevated blood glucose levels reduces said HbA1c in said patient. 13. The method according to claim 1, wherein said administration decreases blood glucose levels by causing a reduction of posttranslational phosphorylation of FOXO1, 3a, and 4. 14. The method according to claim 1, wherein said administration allows said energy deprived cells to restore the glucose transporter system (Glut4). 15. The method according to claim 1, wherein said administration improves insulin resistance of said energy deprived cells. 16. The method according to claim 1, wherein said provided energy restores the pharmacological capability and function of pharmaceutical ligands. 17. The method according to claim 1, wherein dosages of said methyl pyruvate and ethyl pyruvate are dependent on factors relating to said patient, and wherein said factors include co-morbid disease, BMI, and/or physical activity level of said patient. 18. The method according to claim 1, wherein said methyl pyruvate and ethyl pyruvate are administered with said inosine. 19. The method according to claim 1, wherein said methyl pyruvate and ethyl pyruvate are administered with said taurine. 20. The method according to claim 5, wherein said administration occurs at least once a week. 21. The method according to claim 2, wherein said therapeutically effective amount is 4 grams at least once a day, said methyl pyruvate being diluted in water at a concentration of one gram of said methyl pyruvate per liter of water. 22. The method according to claim 2, wherein said therapeutically effective amount is 4 grams diluted in water and administered twice a day. 23. The method according to claim 1, wherein the frequency of said administration depends on the physiological need of the patient. 24. The method according to claim 1, wherein said therapeutically effective amount comprises up to 200 g of said ethyl pyruvate per day and is orally administered in divided doses each day. 25. The method according to claim 1, wherein said therapeutically effective amount comprises from about 1 microgram to about 100 grams of said methyl pyruvate and is administered at least once a day. 26. The method according to claim 25, wherein said therapeutically effective amount comprises 50 grams of said methyl pyruvate at least once a day, said methyl pyruvate being diluted in water at a concentration of one gram of said methyl pyruvate per liter of water. 27. The method according to claim 25, wherein said therapeutically effective amount comprises 10 grams of said methyl pyruvate diluted in water once a day. 28. The method according to claim 1, wherein the administration is performed by administering: a micronized freeze dried powder, a powder packet that is added to a water or other water based beverage, a frozen dessert, an oral gel mixture, being incorporated into a gum base that has a hard shelled immediate and time released delivery, into a time released transdermal patch, an IV solution, or by an intramuscular injection, a parenteral feeding, a suppository format, at least one impregnable oral strip that is dissolvable, at least one dissolvable strip placed on a patient's tongue, in a soluble bi-layer gel capsule, a flavoring agent, or a fragrance. 29. The method according to claim 1, wherein the administration takes place by one of the following routes: ingestion of a frozen dessert or an oral gel mixture;application of a timed releasing transdermal patch to the skin of the patient;injection of an IV solution;an intramuscular injection;placing at least one impregnated oral strip that is dissolvable in the mouth of the patient;placing at least one dissolvable strip on the tongue of the patient;via a flavoring agent;or via a fragrance. 30. A method of treating a patient afflicted with Diabetes Mellitus to reduce HbA1c of said patient, wherein energy is provided to energy deprived cells of said patient, said method consisting of: a) administering, to said patient afflicted with said Diabetes Mellitus, a therapeutically effective amount of methyl pyruvate and ethyl pyruvate, so as to provide said energy to said energy deprived cells via a citric acid cycle in said cells and so as to reduce said HbA1c of said patient;b) administering a plurality of additional agents together with said therapeutically effective amount of said methyl pyruvate and said ethyl pyruvate; andc) monitoring glucose concentration of said patient suffering from said Diabetes Mellitus during said administration;wherein said additional agents consist of alpha lipoic acid, acetyl L-carnitine, taurine, inosine, magnesium chloride, magnesium L-threonate, vitamin E in the form of alpha and gamma tocopherol, vitamin D3 and niacin.
Perrelli, Jonathon E.; Wheatley, David J.; Metlen, Todd; Wheatley, Maxim D.; Bacon, Connor J., System and apparatus for optimizing hydration and for the contextual dispensing of additives.
Perrelli, Jonathon E.; Wheatley, David J.; Wheatley, Maxim D.; Metlen, Todd; Bacon, Connor J., System, method, and apparatus for dispensing variable quantities of additives and controlling characteristics thereof in a beverage.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.